Shares of AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) have received an average rating of "Hold" from the five research firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $19.50.
A number of analysts have weighed in on the company. Zacks Research cut AngioDynamics from a "hold" rating to a "strong sell" rating in a research report on Thursday, July 16th. Canaccord Genuity Group boosted their target price on AngioDynamics from $16.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. Weiss Ratings restated a "sell (d-)" rating on shares of AngioDynamics in a research note on Friday, July 17th. Wall Street Zen raised AngioDynamics from a "hold" rating to a "buy" rating in a report on Saturday. Finally, HC Wainwright lifted their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th.
Check Out Our Latest Stock Report on AngioDynamics
Insider Activity at AngioDynamics
In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the firm's stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.00% of the company's stock.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in AngioDynamics in the second quarter valued at about $49,480,000. Kotler Kevin acquired a new position in AngioDynamics during the 4th quarter worth approximately $21,997,000. Weber Capital Management LLC ADV acquired a new position in AngioDynamics during the 2nd quarter worth approximately $17,649,392,000. Paradigm Capital Management Inc. NY purchased a new position in shares of AngioDynamics during the 2nd quarter worth approximately $8,732,000. Finally, UBS Group AG raised its stake in shares of AngioDynamics by 83.6% during the 3rd quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier's stock worth $12,315,000 after buying an additional 501,881 shares in the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.
AngioDynamics Stock Performance
NASDAQ ANGO opened at $15.95 on Wednesday. The firm's fifty day moving average is $14.11 and its two-hundred day moving average is $12.14. AngioDynamics has a one year low of $9.39 and a one year high of $16.29. The firm has a market cap of $659.21 million, a PE ratio of -18.33 and a beta of 0.33.
AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. Research analysts predict that AngioDynamics will post -0.25 earnings per share for the current year.
AngioDynamics Company Profile
(
Get Free Report)
AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.
In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider AngioDynamics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.
While AngioDynamics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
